Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 7/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 6/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3403350 | 0.89 | CTSB (0.38) | CYP3A4TSHRHTR2CCTSB | |
| SCHEMBL13164007 | 0.79 | HTR6 (0.49) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL17308384 | 0.76 | CTSB (0.55) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL3223437 | 0.76 | HTR6 (0.47) | CYP3A4CXCR2HTR6HTR2C | |
| SCHEMBL18343910 | 0.76 | CA1 (0.41) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL8481331 | 0.76 | HTR6 (0.47) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| Hydrochloric Acid SCHEMBL10666439 | 0.74 | HTR6 (0.46) | LMNACYP3A4GABRA1TSHRGABRG2 | |
| SCHEMBL8482221 | 0.74 | CA1 (0.54) | LMNATSHRCXCR2 | |
| SCHEMBL8484443 | 0.73 | HTR6 (0.50) | HTR6 | |
| SCHEMBL5668214 | 0.73 | CHRM1 (0.40) | LMNACYP3A4GABRA1TSHRGABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744172-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-08-29 | — | — | US | disclosed |
| US-9555030-B2 | Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160279132-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-29 | — | — | US | disclosed |
| US-9290499-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150290212-A1 | THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| WO-2015157125-A1 | THERAPUETIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-15 | — | — | WO | disclosed |
| EP-2571361-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | The University of North Carolina At Chapel Hill (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130059836-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-03-07 | — | — | US | disclosed |
| WO-2011146313-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279132-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | DPYD, TP53, TYMP | LMNA 3796/4885CYP3A4 82/4885GABRA1 3828/4885 |
| US-20150290212-A1 | THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | MERTK, TK1, FLT3 | LMNA 4516/4885CYP3A4 2494/4885GABRA1 3744/4885 |
| US-20130059836-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | DPYD, TYMP, TP53 | LMNA 3810/4885CYP3A4 104/4885GABRA1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.